We recently compiled a list of the 20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy. In this article, we ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis ...

Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $38.23. The company has a one-year high of $40.02 and a one-year low of $20.14. Currently, Exelixis has an average ...

We've been asking ourselves recently if the market has placed a fair valuation on Exelixis. Let's dive into some of the ...

Penumbra, Inc. today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, ...

Individuals suffering from depression, stress or mental fog can now find relief at Spa Southwest in Dubuque, Iowa, a state-of-the-art wellness center offering EXOMIND, a noninvasive brain stimulation ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis ...

Exelixis's EXEL Get Free Report short percent of float has risen 25.73% since its last report. The company recently reported ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.